GlobeNewswire by notified

Total number of shares and voting rights in Zealand Pharma at March 31, 2024

Share

Company announcement – No. 21 / 2024

Total number of shares and voting rights in Zealand Pharma at March 31, 2024

Copenhagen, Denmark, March 31, 2024 Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. 

In Company announcement No. 11/2024 from March 5, 2024, and in company announcement No. 19/2024, from March 26,2024, Zealand announced an increase in share capital relating to exercise of employee warrants. Following these announcements, the table below lists the total number of shares and voting rights in Zealand up to and including March 31, 2024.



Date
Number of shares
(nominal value of DKK 1 each)
Share capital
(nominal value in DKK)
Number of voting rights
March 31, 2024 62,648,011 62,648,011 62,648,011


# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Contact:

Adam Lange
Investor Relations Officer
Zealand Pharma
Email: akl@zealandpharma.com
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Nokia Corporation: Repurchase of own shares on 12.04.202412.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 12 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 12.04.2024 Espoo, Finland – On 12 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL557,4733.19CEUX--BATE--AQEU--TQEX--Total557,4733.19 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

EPH European Property Holdings PLC Suggests Amendments to the Terms of its Listed Bonds ISIN CH117734830212.4.2024 20:00:00 CEST | Press release

12th April 2024, Limassol, Cyprus I Ad hoc announcement pursuant to Art. 53 LR EPH European Property Holdings PLC (the “Company” or “EPH”) has decided to suggest to the holders of the Company’s bonds with ISIN CH1177348302 and with a total nominal value of EUR 122,175,000 to amend certain terms of these bonds: Replacement of the current interest rate of 2.25 % p.a. with an interest rate of 3.50% p.a.; andA term prolongation of 5 years of the Bonds until 31 May 2029 The bondholders are requested to consent or reject the suggested amendments until 13th May 2024. Subject to having received consents by all bondholders the amendments to the Terms of the Bonds shall become effective on 1st June 2024. EPH EUROPEAN PROPERTY HOLDINGS PLC is an investment company listed on SIX Swiss Exchange and holds a commercial property portfolio with a total value of approx. EUR 900 million, including real estate assets in Berlin, Hamburg, Stuttgart, Dresden, Switzerland and Vienna. Additional information on

Nexstim Plc Resolved on a New Stock Option Plan 2024H12.4.2024 20:00:00 CEST | Press release

Company Announcement, Helsinki, 12 April 2024 at 9 PM (EEST) Nexstim Plc Resolved on a New Stock Option Plan 2024H Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that the Board of Directors of Nexstim resolved on 12 April, 2024, to launch a new stock option plan 2024H aimed at the Board of Directors of the Company by virtue of an authorization granted by the Annual General Meeting of Shareholders of the company on March 28, 2024, and according to the AGM resolution. The Company has a weighty financial reason for the issue of stock options since the stock options are intended to form part of the incentive and commitment program. The purpose of the stock options is to encourage the members of the Board of Directors to work and co-operate on a long-term basis to increase shareholder value. The purpose of the stock options is also to commit the members of the Board of Directors to the Company. The maximum total number of stock options 2024H issued is 37,500 and they entitle the

SalMar - Nøkkelinformasjon ved kontantutbytte for SalMar ASA12.4.2024 19:16:00 CEST | Pressemelding

Utbyttebeløp: 35,0 kroner per aksje Annonsert valuta: NOK Siste dag inklusive: 06.06.2024 Ex-dato: 07.06.2024 Record date (eierregisterdato): 10.06.2024 Betalingsdato: På eller omkring: 20.06.2024 Vedtaksdato: 06.06.2024 For mer informasjon, kontakt: Håkon Husby, IR-ansvarlig Tel: +47 936 30 449 Email: hakon.husby@salmar.no Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

SalMar - Key information relating to the cash dividend to be paid by SalMar ASA12.4.2024 19:16:00 CEST | Press release

Dividend amount: 35.0 per share Declared currency: NOK Last day including right: 06.06.2024 Ex-date: 07.06.2024 Record date: 10.06.2024 Payment date: On or about 20.06.2024 Date of approval: 06.06.2024 For more information, please contact: Håkon Husby, Head of Investor Relations Tel: +47 936 30 449 Email: hakon.husby@salmar.no This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

HiddenA line styled icon from Orion Icon Library.Eye